MorphoSys AG (MOR)

NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with payments previously received, results in total cash proceeds of $530 million on the $300 million investment that was made in September 2022. The company generated an attractive return by monetizing these future fixed payments at a low discount rate of 5.35% and will redeploy these proceeds into higher returning investment opportunities, including repurchasing its shares and acquiring attractive new royalties.

Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying 330 jobs would be affected.

Novartis' CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data.

MUNICH, GERMANY / ACCESSWIRE / August 27, 2024 / MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company's Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the transfer of MorphoSys' minority shareholders' shares to Novartis BidCo Germany AG (hereinafter referred to as "Novartis"), the company's majority shareholder, against a cash compensation of € 68.00 per share ("merger squeeze-out").

NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating MorphoSys AG ( N asdaq : MOR ) , relating to a tender offer from Novartis BidCo AG. Under the terms of the offer, MorphoSys shareholders will receive €68.00 per share they own.

NEW YORK , July 15, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating MorphoSys AG (Nasdaq: MOR ), relating to a tender offer from Novartis BidCo AG.

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”). MorphoSys currently anticipates that it will file with the Securities and Exchange Commission (the “SEC”) a Form 25, Notification of.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of MorphoSys AG (NASDAQ: MOR) to Novartis for €68.00 per share in cash is fair to MorphoSys shareholders. Halper Sadeh encourages MorphoSys shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether MorphoSys and its board o.

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as “Novartis”) also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a.

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany AG proposed to enter negotiations with the MorphoSys AG Management Board on a merger agreement.

Under the MOR-EV program, the Mullen THREE EV truck, with a suggested MSRP of $68,500, now qualifies for a Massachusetts state cash rebate of up to $15,000

MorphoSys AG (NASDAQ:MOR – Free Report) – Stock analysts at Leerink Partnrs raised their Q2 2024 EPS estimates for MorphoSys in a research report issued to clients and investors on Wednesday, May 15th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($0.54) per share for the quarter, up from their prior forecast of ($0.56). The consensus estimate for MorphoSys’ current full-year earnings is ($2.43) per share. Leerink Partnrs also issued estimates for MorphoSys’ Q3 2024 earnings at ($0.43) EPS, Q4 2024 earnings at ($0.41) EPS, FY2024 earnings at ($2.76) EPS, FY2025 earnings at ($1.82) EPS, FY2026 earnings at ($1.27) EPS and FY2027 earnings at ($1.26) EPS. MorphoSys (NASDAQ:MOR – Get Free Report) last issued its quarterly earnings results on Monday, April 29th. The company reported ($2.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($1.73). The business had revenue of $29.86 million for the quarter, compared to analyst estimates of $48.99 million. MorphoSys had a negative return on equity of 694.31% and a negative net margin of 226.79%. Separately, Wells Fargo & Company reissued an “equal weight” rating and issued a $18.25 target price (up from $17.00) on shares of MorphoSys in a research report on Thursday, March 14th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $11.78. Check Out Our Latest Stock Analysis on MOR MorphoSys Price Performance NASDAQ MOR opened at $19.00 on Monday. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.38 and a quick ratio of 1.38. The stock’s fifty day moving average price is $18.07 and its 200 day moving average price is $13.45. MorphoSys has a 1 year low of $4.18 and a 1 year high of $19.50. The company has a market cap of $2.86 billion, a price-to-earnings ratio of -5.46 and a beta of 1.15. Institutional Investors Weigh In On MorphoSys Several hedge funds have recently added to or reduced their stakes in the business. Carlson Capital L P purchased a new stake in MorphoSys in the first quarter valued at $17,241,000. Henry James International Management Inc. boosted its holdings in MorphoSys by 105.8% in the first quarter. Henry James International Management Inc. now owns 88,506 shares of the company’s stock valued at $1,605,000 after purchasing an additional 45,506 shares during the last quarter. SAL Trading LLC purchased a new stake in MorphoSys in the first quarter valued at $486,000. Susquehanna International Group Ltd. purchased a new stake in MorphoSys in the first quarter valued at $1,333,000. Finally, BNP Paribas Financial Markets boosted its holdings in MorphoSys by 130.4% in the first quarter. BNP Paribas Financial Markets now owns 32,533 shares of the company’s stock valued at $590,000 after purchasing an additional 18,413 shares during the last quarter. 18.38% of the stock is owned by hedge funds and other institutional investors. About MorphoSys (Get Free Report) MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.

Trevena, Inc. (NASDAQ:TRVN – Free Report) – HC Wainwright dropped their Q2 2024 earnings per share (EPS) estimates for Trevena in a research report issued to clients and investors on Thursday, May 16th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will earn ($0.37) per share for the quarter, down from their previous forecast of ($0.30). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Trevena’s current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Trevena’s Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings at ($1.29) EPS, FY2025 earnings at ($0.79) EPS, FY2026 earnings at ($0.99) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($0.90) EPS. Trevena (NASDAQ:TRVN – Get Free Report) last issued its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.01. The firm had revenue of $0.02 million during the quarter. Separately, StockNews.com began coverage on Trevena in a research report on Thursday. They issued a “sell” rating on the stock. Read Our Latest Research Report on Trevena Trevena Price Performance NASDAQ TRVN opened at $0.40 on Monday. The business’s fifty day moving average is $0.43 and its 200 day moving average is $0.56. The company has a market capitalization of $7.42 million, a PE ratio of -0.15 and a beta of 1.11. Trevena has a fifty-two week low of $0.30 and a fifty-two week high of $1.35. The company has a debt-to-equity ratio of 8.35, a quick ratio of 4.66 and a current ratio of 3.60. Institutional Trading of Trevena An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC bought a new position in shares of Trevena, Inc. (NASDAQ:TRVN – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena as of its most recent filing with the Securities and Exchange Commission (SEC). 13.56% of the stock is currently owned by institutional investors. Trevena Company Profile (Get Free Report) Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. See Also Five stocks we like better than Trevena What is MarketRank? How to Use it MarketBeat Week in Review – 5/13 – 5/17 What is the Euro STOXX 50 Index? Take-Two Interactive Software Offers 2nd Chance for Investors 3 Ways To Invest In Coffee, Other Than Drinking It Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook

MorphoSys acquired by Novartis for EUR 2.7 billion, showcasing a significant premium over pre-announcement share price. The deal is expected to go through smoothly based on regulatory approvals received and successful precedents of similar M&A transactions. Pelabresib, MorphoSys's leading candidate for myelofibrosis treatment, shows promising results and potential as a game-changer in the field.

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024. “The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first half of 2024. The acceptance period for the acquisition is currently underway, and both our Management Board and Supervisory Board unanimously recommend that our shareholders accept the offer and tender their shares given the highly attractive and equitable.

Morphosys said its takeover by Novartis was still expected to be closed in the first half of this year, in a statement responding to a possible safety risk reported by specialist news website STAT News that knocked the company's share price on Monday.